Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Drug Synergy Screen and Network Modeling in Dedifferentiated Liposarcoma (DDLS) part 2

ABSTRACT: Analysis of DNA copy number variations in two DDLS tumor-derived cell lines DDLS8817 and LPS141 growing in culture in basal conditions The goal of this DNA copy number analysis was to determine if genes used in signaling network modeling in DDLS were amplified or deleted

ORGANISM(S): Homo sapiens

PROVIDER: GSE50750 | GEO | 2013/09/24

SECONDARY ACCESSION(S): PRJNA218741

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Drug Synergy Screen and Network Modeling in Dedifferentiated Liposarcoma (DDLS) part 2

Project description:Analysis of DNA copy number variations in two DDLS tumor-derived cell lines DDLS8817 and LPS141 growing in culture in basal conditions The goal of this DNA copy number analysis was to determine if genes used in signaling network modeling in DDLS were amplified or deleted Genomic DNA was isolated from asynchronously growing DDLS8817 and LPS141 cultures growing in basal conditions using the Qiagen DNAy kit.

2013-09-24 | E-GEOD-50750 | biostudies-arrayexpress

Drug Synergy Screen and Network Modeling in Dedifferentiated Liposarcoma (DDLS) part 1

Project description:Analysis of gene expression levels in two DDLS tumor-derived cell lines DDLS8817 and LPS141 growing in culture in basal conditions The goal of this gene transcript study was to determine the expression level of genes used in signaling network modeling in DDLS RNA was isolated from asynchronously growing DDLS8817 and LPS141 cultures growing in basal conditions using the Qiagen RNEasy kit. Three replicates of each cell line

2013-09-24 | E-GEOD-50749 | biostudies-arrayexpress

Drug Synergy Screen and Network Modeling in Dedifferentiated Liposarcoma (DDLS) part 1

2013-09-24 | GSE50749 | GEO

Drug Synergy Screen and Network Modeling in Dedifferentiated Liposarcoma (DDLS)

Project description:This SuperSeries is composed of the SubSeries listed below. Refer to individual Series

2013-09-24 | E-GEOD-50751 | biostudies-arrayexpress

Drug Synergy Screen and Network Modeling in Dedifferentiated Liposarcoma (DDLS)

Project description:This SuperSeries is composed of the SubSeries listed below.

2013-09-24 | GSE50751 | GEO

Drug synergy screen and network modeling in dedifferentiated liposarcoma identifies CDK4 and IGF1R as synergistic drug targets.

Project description:Dedifferentiated liposarcoma (DDLS) is a rare but aggressive cancer with high recurrence and low response rates to targeted therapies. Increasing treatment efficacy may require combinations of targeted agents that counteract the effects of multiple abnormalities. To identify a possible multicomponent therapy, we performed a combinatorial drug screen in a DDLS-derived cell line and identified cyclin-dependent kinase 4 (CDK4) and insulin-like growth factor 1 receptor (IGF1R) as synergistic drug targets. We measured the phosphorylation of multiple proteins and cell viability in response to systematic drug combinations and derived computational models of the signaling network. These models predict that the observed synergy in reducing cell viability with CDK4 and IGF1R inhibitors depends on the activity of the AKT pathway. Experiments confirmed that combined inhibition of CDK4 and IGF1R cooperatively suppresses the activation of proteins within the AKT pathway. Consistent with these findings, synergistic reductions in cell viability were also found when combining CDK4 inhibition with inhibition of either AKT or epidermal growth factor receptor (EGFR), another receptor similar to IGF1R that activates AKT. Thus, network models derived from context-specific proteomic measurements of systematically perturbed cancer cells may reveal cancer-specific signaling mechanisms and aid in the design of effective combination therapies.

| S-EPMC4000046 | biostudies-literature

Validation of dedifferentiated liposarcoma (DDLS) cell lines with the original tumors via copy number alteration analysis [array]

Project description:We validated patient's tumor-derived cell lines of liposarcoma by analysing copy number alterations using aCGH or WGS and comparing with the original tumor tissues. examination of copy number alterations for 2 cell lines, one of the original tumor, one PDX-tumor and its original tumor.

2021-12-31 | GSE184701 | GEO

Validation of dedifferentiated liposarcoma (DDLS) cell lines with the original tumors via copy number alteration analysis [sequencing]

Project description:We validated patient's tumor-derived cell lines of liposarcoma by analysing copy number alterations using aCGH or WGS and comparing with the original tumor tissues.

2021-12-31 | GSE184700 | GEO

Validation of dedifferentiated liposarcoma (DDLS) cell lines with the original tumors via copy number alteration analysis

Project description:Validation of dedifferentiated liposarcoma (DDLS) cell lines with the original tumors via copy number alteration analysis

| PRJNA765683 | ENA

Validation of dedifferentiated liposarcoma (DDLS) cell lines with the original tumors via copy number alteration analysis [sequencing]

Project description:Validation of dedifferentiated liposarcoma (DDLS) cell lines with the original tumors via copy number alteration analysis [sequencing]

| PRJNA765692 | ENA

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data